Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Monsanto Company (MON)’s Growing Yields

Page 1 of 2

Monsanto Company (NYSE:MON) exemplifies the increasing population, expanding food demand, and growing food production story. The company’s main segment, corn seed, continues to capitalize on this megatrend by providing higher yielding hybrids to farmers. Growth in their soybean platforms, while flat recently, will rise through increased licensing and the introduction of new higher yielding products. Additionally, the company’s strong balance sheet provides stability, opportunities for reinvestment, and growing shareholder returns.

genetically modified foods


Monsanto Company (NYSE:MON) has doubled the price of its corn seeds over the past ten years through the introduction of higher yielding hybrids. To the farmer, a relatively small increase in seed costs is easily outweighed by the increased profits from the higher crop yield. As the share of newly introduced hybrids increases in Monsanto Company (NYSE:MON)’s portfolio mix so too does the net selling price. Because of this mix benefit, the company is improving its price by 5-10% per year.

Source: MON_Second Quarter 2013 Earnings.pdf

Monsanto Company (NYSE:MON) is also increasing its volumes by introducing higher yielding hybrids. Farmers are not only willing to pay more but the company captures a higher market and acreage share by offering higher yields. Monsanto Company (NYSE:MON) has doubled its seed volume since 2006 by offering higher value seeds.

In April, Monsanto Company (NYSE:MON) announced an agreement with The Dow Chemical Company (NYSE:DOW) to cross-license corn technologies. Monsanto will license a The Dow Chemical Company (NYSE:DOW) herbicide trait and Dow will have access to Monsanto’s upcoming, third generation rootworm tech. Financial terms were not disclosed. For Monsanto, the agreement will bring an additional mode of action to their corn platform that will benefit their farmer customers’ yields. For Dow the agreement is the first licensing of their Enlist trait in corn. The agricultural science segment at Dow is growing and currently represents about 9% of sales. About 2% of total sales come specifically from seed and trait technologies.


Monsanto has a multi-billion dollar opportunity in soybeans over the next five years. First, trials of its new Intacta RR2 Pro in Brazil show a significant yield increase over Roundup Ready. The trials indicate a greater than 4 bushel per acre increase and yield the farmer an additional $80 per acre (including other platform savings). Large scale, open-minded Brazilian farmers are early adopters and Intacta RR2 Pro is a 100 million acre opportunity for Monsanto.

Source: MON_Q2F13_Earnings.pdf

Licensing is also proving growth opportunities in soy. In March, Monsanto announced an agreement to provide, DuPont Fabros Technology, Inc. (NYSE:DFT) with soybean trait technology. The deal is broken down into two parts. First, DuPont Fabros Technology, Inc. (NYSE:DFT) will make four annual payments from 2014-2017 that total $802 million. Then, from 2018 until 2023, DuPont will pay royalties on a per unit basis for Genuity Roundup Ready 2 technology. The royalty payments are subject to minimums and should total at least $950 million. Like Dow, DuPont’s agriculture segment is growing and represents a larger piece of its revenue pie at 28%. DuPont focuses on both seeds and agricultural chemicals.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!